3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
CNS
1
Conditions
Respiratory Tract Diseases
1
Neoplasms
1
Meningeal Carcinomatosis
1
Lung Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Brain Neoplasms
1
Interventions
pembrolizumab
3
Carboplatin
3
selpercatinib
2
durvalumab
2
Pemetrexed
2
Cisplatin
2
taletrectinib
1
sotorasib
1
repotrectinib
1
pralsetinib
1
ceralasertib
1
Telescopes
1
Radiosurgery
1
Paclitaxel
1
Gemcitabine
1
Gefitinib
1
Erlotinib Hydrochloride
1
Bevacizumab
1
AZD3759
1
4-((1,4,8,11-tetraazacyclotetradec-1-yl)methyl)benzoic acid
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Respiratory Tract Diseases
×
AZD3759
×
1 year
×
Clear all
NCT03653546
2025-09-10
BM
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3
Completed
492 enrolled